Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
NASDAQ: SHPH · Real-Time Price · USD
0.898
+0.007 (0.79%)
At close: Nov 20, 2024, 4:00 PM
0.960
+0.062 (6.86%)
Pre-market: Nov 21, 2024, 6:35 AM EST
SHPH Employees
Shuttle Pharmaceuticals Holdings had 8 employees as of December 31, 2023. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,148,354
Market Cap
2.00M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 1 | 14.29% |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | -1 | -16.67% |
| Dec 31, 2016 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xylo Technologies | 84 |
| Scorpius Holdings | 84 |
| Fresh2 Group | 75 |
| ENDRA Life Sciences | 21 |
| Biodexa Pharmaceuticals | 21 |
| Phio Pharmaceuticals | 9 |
| GRI Bio | 4 |
| Qualigen Therapeutics | 4 |
SHPH News
- 7 days ago - Shuttle Pharma Provides Third Quarter 2024 Corporate Update - GlobeNewsWire
- 22 days ago - Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 23 days ago - Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma - GlobeNewsWire
- 2 months ago - Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma - GlobeNewsWire
- 2 months ago - Shuttle Pharma Provides Second Quarter 2024 Corporate Update - GlobeNewsWire
- 3 months ago - Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) - GlobeNewsWire
- 3 months ago - Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - GlobeNewsWire
- 4 months ago - Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE - GlobeNewsWire